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Objectives The purpose of this study was to develop a risk stratification score to predict warfarin-associated hemorrhage.
Background Optimal decision making regarding warfarin use for atrial fibrillation requires estimation of hemorrhage risk.
Methods We followed up 9,186 patients with atrial fibrillation contributing 32,888 person-years of follow-up on warfarin,
obtaining data from clinical databases and validating hemorrhage events using medical record review. We used
Cox regression models to develop a hemorrhage risk stratification score, selecting candidate variables using
bootstrapping approaches. The final model was internally validated by split-sample testing and compared with 6
published hemorrhage risk schemes.
Results We observed 461 first major hemorrhages during follow-up (1.4% annually). Five independent variables were
included in the final model and weighted by regression coefficients: anemia (3 points), severe renal disease
(e.g., glomerular filtration rate 30 ml/min or dialysis-dependent, 3 points), age 75 years (2 points), prior
bleeding (1 point), and hypertension (1 point). Major hemorrhage rates ranged from 0.4% (0 points) to 17.3%
per year (10 points). Collapsed into a 3-category risk score, major hemorrhage rates were 0.8% for low risk (0 to
3 points), 2.6% for intermediate risk (4 points), and 5.8% for high risk (5 to 10 points). The c-index for the con-
tinuous risk score was 0.74 and 0.69 for the 3-category score, higher than in the other risk schemes. There was
net reclassification improvement versus all 6 comparators (from 27% to 56%).
Conclusions A simple 5-variable risk score was effective in quantifying the risk of warfarin-associated hemorrhage in a large
community-based cohort of patients with atrial fibrillation. (J Am Coll Cardiol 2011;58:395–401) © 2011 by
the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.03.031Oral anticoagulants such as warfarin can substantially re-
duce the thromboembolic consequences of atrial fibrillation
(1). However, anticoagulant-associated hemorrhage deters
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2011, accepted March 29, 2011.many clinicians from prescribing warfarin (2). Accurate risk
stratification according to hemorrhage risk would facilitate
the anticoagulation decision for individual patients, and
could help control for varying hemorrhage risk across
different studies or when comparing the safety of various
antithrombotic agents. We describe the development and
internal validation of a new hemorrhage risk stratification
tool and compare its performance to other published hem-
orrhage risk schemes.
Methods
The ATRIA (Anticoagulation and Risk Factors in Atrial
Fibrillation) study followed up 13,559 adults with nonval-
vular, nontransient atrial fibrillation enrolled in Kaiser
Permanente of Northern California, a large integrated
healthcare system. Details of the cohort assembly have been
described previously; briefly, subjects were identified by
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International Classification of
Diseases-Ninth Revision, Clini-
cal Modification (ICD-9) codes
for atrial fibrillation between July
1, 1996, and December 31, 1997,
and followed up through Sep-
tember 30, 2003 (3,4). Warfarin
exposure was determined using a
previously described and vali-
dated algorithm based on the
number of days supplied per pre-
scription, refill patterns, and in-
tervening international normal-
ized ratio measurements (3). Clinical variables were
identified using ICD-9 codes, pharmacy prescriptions, and
laboratory databases (3).
We identified 6 published, validated risk stratification
schemes developed to predict warfarin-associated hemor-
rhage (Table 1) and searched for those specific risk factors in
the ATRIA study cohort (5-10). Variables unavailable in
the ATRIA cohort (e.g., patient genotype) or not directly
applicable to atrial fibrillation (e.g., acute pulmonary embo-
lism) were not included as potential variables. Prior bleeding
history was defined as any prior outpatient or inpatient
ICD-9 diagnosis code of hemorrhage, including by specific
organ system (e.g., prior intracranial or gastrointestinal
bleeding), in the aggregate (e.g., all-cause prior bleeding),
and by timing (within 90 days or 90 days). High fall risk
was defined as any prior hospitalization with a discharge
diagnosis code indicating mechanical fall that occurred in
either the inpatient or outpatient setting.
Clinical laboratory databases were used to identify anemia
(hemoglobin 13 g/dl in men and 12 g/dl in women),
thrombocytopenia (platelet count 90,000), and renal in-
sufficiency (measured by serum creatinine and estimated
glomerular filtration rate) (11). Abnormal laboratory values
were considered abnormal from 3 months before to 1 year
after the date of the measurement, censored by a preceding
or subsequent normal test value. If results were unavailable
within the time window, the test was assumed normal based
on the assumption that tests would be ordered if there were
clinical suspicions.
Clopidogrel and ticlopidine exposure was determined
from pharmacy databases, and duration was defined from
prescription start date to 2 months after the end of the
medication supply. Accurate assessment of aspirin and
nonsteroidal anti-inflammatory drugs exposure was not
possible since these medications were predominantly ob-
tained without prescription.
Major hemorrhage outcomes. We searched computerized
databases for primary discharge ICD-9 codes for extracra-
nial hemorrhages (i.e., gastrointestinal, genitourinary, ret-
roperitoneal) and primary and secondary diagnoses of intra-
cranial hemorrhage, including intracerebral, subarachnoid,
Abbreviations
and Acronyms
HEMORR2HAGES 
hepatic/renal disease,
ethanol abuse, malignancy,
older age, reduced platelet
count, rebleeding risk,
hypertension, anemia,
genetic factors, excessive
fall risk, and stroke
ICD-9  International
Classification of Diseases-
Ninth Revision, Clinical
Modificationor subdural hemorrhages (Online Appendix). Medical hcharts from potential hemorrhagic events were reviewed by
a clinical outcomes committee using a formal study proto-
col. Only events that occurred during or within 5 days of
preceding warfarin exposure were included. Hemorrhages
not present on admission that occurred during the hospi-
talization or as a result of a procedure were excluded. We
restricted the analysis to “major hemorrhages,” defined as
fatal, requiring transfusion of 2 U packed blood cells, or
hemorrhage into a critical anatomic site (e.g., intracranial,
retroperitoneal).
Statistical analyses. All follow-up periods on warfarin
were included in the analysis. Cox proportional hazards
regression models using time-varying covariates were used
to examine the relationships between potential risk factors
and hemorrhage outcomes with time origins set at the
beginning of each follow-up period. Risk factor values were
updated over follow-up with the proviso that no values were
changed within 7 days of an endpoint bleeding event.
The cohort was randomly divided into a split-sample
“derivation” and “validation” cohort using a 2:1 ratio;
models using time-varying covariates were developed in the
derivation cohort and performance tested in the validation
cohort. Covariates associated with major hemorrhage with a
hazard ratio 1.5 were considered for potential inclusion in
the final multivariable model. Since variable selection pro-
cedures may produce unstable results, we applied backward
elimination selection on 1,000 bootstrap samples from the
derivation set, with 0.05 the significance level set for
emoving a variable. Final model variables were those
elected in50% of bootstrap samples (12). Model discrim-
nation was evaluated using the c-index (13), and calibration
y the goodness-of-fit test. Variables from the final multi-
ariable Cox regression model were converted to a risk
core, with points assigned to each predictor approximately
roportional to the magnitude of the regression coefficients
ounded to the nearest integer.
The risk score was collapsed into “low,” “intermediate,”
nd “high” risk groups based on the observed major hem-
rrhage rate. Because there are no definitive or clinically
etermined cut-points for rates of major hemorrhage at
hich anticoagulation would be universally contraindicated,
e chose thresholds in our point score that appeared to
ptimally aggregate low- and high-risk groups. We then
pplied the ATRIA study model and 6 other risk schemes
sing time-varying covariates to the ATRIA cohort to
ompare model performance using the c-index, risk strati-
cation capacity (the proportion of the cohort assigned to
linically meaningful risk categories), and by a recently
ublished extension of the net reclassification improvement
etric (14). For net reclassification improvement calcula-
ions, all schemes were compared using a low/intermediate/
igh categorization to provide a common scale. This study
as approved by the respective institutional committees on
uman research boards.
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July 19, 2011:395–401 The ATRIA Hemorrhage Risk Prediction ScoreResults
There were 9,186 subjects in the ATRIA study cohort, contrib-
uting 32,888 person-years of warfarin exposure (median warfarin
duration 3.5 years [interquartile range: 1.2 to 6.0 years]). Because
anticoagulated patients could discontinue warfarin and subse-
quently resume therapy, individual patients could contribute mul-
tiple periods on warfarin; 2,790 patients (30%) had1 period on
arfarin and 709 patients (8%) had 2 periods on warfarin.
odel development. We identified 461 validated incident
Risk Stratification Schemes Used to Predict Warfarin-Associated HTable 1 Risk Stratification Schemes Used to Predict Warfarin-A
Risk Scheme (Ref. #)/First Author, Year (Ref. #) Risk Fa
Outpatient Bleeding Index (5)
Developed in patients newly starting warfarin
after hospital discharge
Age 65 yrs (1 point)
Prior stroke (1 point)
Prior GI bleeding (1 point)
Recent MI, diabetes mellitus
creatinine 1.5 mg/dl (1
Kuijer et al., 1999 (6)
Developed in patients with acute
thromboembolism
Age 60 yrs (1.6 points)
Female (1.3 points)
Malignancy (2.2 points)
Kearon et al., 2003 (7)
Developed in patients with acute venous
thromboembolism enrolled in clinical trial.†
Risk score categories developed and validated
by Gage et al. (8)
Age 65 yrs (1 point)
Prior stroke (1 point)
Prior peptic ulcer disease (1
Prior GI bleeding (1 point)
Creatinine 1.5 mg/dl (1 po
Anemia or thrombocytopeni
Liver disease (1 point)
Diabetes mellitus (1 point)
Antiplatelet therapy (1 point
HEMORR2HAGES
Gage et al., 2006 (8)
Developed in hospitalized Medicare patients with
atrial fibrillation discharged on warfarin
Hepatic or renal disease (1 p
Ethanol abuse (1 point)*
Malignancy (1 point)
Older age 75 yrs (1 point)
Reduced platelet count or fu
Rebleeding risk (2 points)
Hypertension (1 point)
Anemia (1 point)
Genetic factors (1 point)*
Excessive fall risk or neurops
Stroke (1 point)
Shireman et al., 2006 (9)
Developed in hospitalized Medicare patients with
atrial fibrillation discharged on warfarin
Age 70 yrs
Female
Remote bleeding event
Recent bleeding event
Alcohol or drug abuse*
Diabetes mellitus
Anemia (Hct 30% during in
Antiplatelet drugs (aspirin, c
at discharge)*
Risk score  0.49 (age 70
 0.58 (remote bleed) 
 0.71 (alcohol/drug abu
 0.86 (anemia)  0.32
RIETE risk scheme
Ruiz-Gimenez et al., 2008 (10)
Developed in patients with acute venous
thromboembolism
Recent major bleeding (15
thrombotic event) (2 poin
Creatinine 1.2 mg/dl (1.5
Anemia (1.5 points)
Malignancy (1 point)
Clinically overt pulmonary em
Age 75 yrs (1 point)
*Data on ethanol abuse, drug abuse, aspirin, and genetic factors not available in the ATRIA (Antic
applied to Gage et al. (8) atrial fibrillation cohort.
GI gastrointestinal; Hct hematocrit; HEMORR2HAGES Hepatic/renal disease, Ethanol abus
Excessive fall risk, and Stroke; MI  myocardial infarction; PY  person-years; RIETE  Registroarfarin-associated major hemorrhages, an annualized rate vf 1.40% hemorrhages per year. The derivation cohort
ontained 307 major hemorrhages among 6,123 patients,
nd the validation cohort 154 major hemorrhages among
,063 patients.
Table 2 compares the characteristics of subjects with and
ithout major hemorrhage in the derivation cohort. Vari-
bles associated with major hemorrhage at a hazard ratio
1.5 on bivariate analysis were considered for the final
odel and tested in 1,000 bootstrap samples. Among the
rhageiated Hemorrhage
Risk Category Points
Major Bleeding Rate
in Validation Cohorts
atocrit 30%,
if any of the above)
Low 0 3% at 12 months
Intermediate 1–2 8% at 12 months
High 3–4 30% at 12 months
Low 0 0.6% at 3 months
Intermediate 0,3 2% at 3 months
High 3 7% at 3 months
int)
Low 0–1 2.5 per 100 PY
Intermediate
High
2
3
4
6.5 per 100 PY
9.3 per 100 PY
15.3 per 100 PY
(1 point)*
ric disease (1 point)
Low 0–1 1.9–2.5 per 100 PY
Intermediate 2–3 5.3–8.4 per 100 PY
High 4 10.4–12.3 per 100 PY
ospitalization)
rel, or ticlodipine
32 (female)
recent bleed)
0.27 (diabetes)
atelet use)
Low 1.07 0.9% within 90 days
Intermediate 1.07, 2.19 2.0% within 90 days
High 2.19 5.4% within 90 days
before
)
* (1 point)
Low 0 0.1% at 3 months
Intermediate 1–4 2.8% at 3 months
High 4 6.2% at 3 months
tion and Risk Factors in Atrial Fibrillation) study database. †Hemorrhage rates when risk scheme
nancy, Older age, Reduced platelet count, Rebleeding risk, Hypertension, Anemia, Genetic factors,
tizado de la Enfermedad TromboEmbo´lica.emorssoc
ctors
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The ATRIA Hemorrhage Risk Prediction Score July 19, 2011:395–401“severe renal disease” (defined as estimated glomerular
filtration rate 30 ml/min or dialysis dependent) and “any
prior hemorrhage diagnosis (all-cause)” were selected over
alternative definitions based on bootstrap analysis. Five final
variables emerged in 50% of bootstrap samples: anemia,
severe renal disease, age 75 years, any prior hemorrhage
iagnosis, and diagnosed hypertension. Based on the final
odel’s regression coefficients, anemia and severe renal
isease were assigned 3 points, age 75 years 2 points, and
rior hemorrhage and diagnosed hypertension 1 point each,
esulting in a risk scheme with a possible range of 0 to 10
oints (Table 3).
odel validation and performance. When applied to the
alidation set, the model generated regression coefficients
Clinical Characteristics of 6,123 Subjects WithFollowed-Up for 21,923 Person-Years on WarfarSustained M jor Hemorrhage and Subjects With
Table 2
Clinical Char cteristics of 6,123 Su
Followed-Up for 21,923 Person-Yea
Sustained Major Hemorrhage and S
Clinical Characteristics
With M
Hemorr
(n  3
Age, yrs
65 91.
70 79.
75 61.
Female 37.
Nonwhite race 13.
Any diagnosis of cancer 18.
Prior stroke 17.
Diagnosed hypertension 64.
Diabetes mellitus 22.
Recent myocardial infarction 0.
Prior intracranial hemorrhage 0.
Prior gastrointestinal hemorrhage 12.
Prior other hemorrhage 2.
Prior hematuria 10.
Any prior hemorrhage diagnosis (all cause) 24.
Any prior hemorrhage diagnosis
90 days prior 21.
Within 90 days 2.
Diagnosed peptic ulcer disease 5.
Diagnosed cirrhosis 1.
History of hepatitis 1.
Prior hospital discharge diagnosis of
mechanical fall
6.
Diagnosed neuropsychiatric disease 3.
On clopidogrel or ticlopidine 0.
Anemia 18.
Platelet count 90,000 0.
Serum creatinine, mg/dl
2.0 4.
1.5 9.
1.2 18.
eGFR 30 ml/min 5.
On dialysis 0.
Hemoglobin A1c 7.0 4.
Values are % person-years unless otherwise indicated.
CI  confidence interval; eGFR  estimated glomerular filtration raimilar to those in the derivation dataset, with good dis- trimination (c-index 0.74 [0.70 to 0.78]) and acceptable
alibration by the goodness-of-fit test (p  0.29). Bleeding
ates in the combined cohort ranged from 0.4% to 17.3%
er year (Table 4). The continuous risk score was collapsed
o a 3-category scheme, where “low-risk” (0 to 3 points)
atients had hemorrhage rates of 1% per year, and
high-risk” (5 to 10 points) patients had rates 5% per year
Table 4). The high-risk category effectively concentrated
emorrhage events such that 42% of hemorrhage events
ccurred in only 10.2% of cohort person-years. The vast
ajority of remaining patients and person-years were low
isk (Fig. 1).
Compared with other risk schemes, the ATRIA study
isk score had the highest c-index point estimates for both
l Fibrillation in Derivation Cohortmparing Subjects Whoajo Hemorrhagts With Atrial Fibrillati n in Derivation Cohort
Warfarin, Comparing Subjects Who
ts Without Major Hemorrhage
Without Major
Hemorrhage
(n  5,816)
Hazard Ratio
(95% CI) p Value
84.3 3.3 (2.1–5.0) 0.001
72.1 2.7 (2.0–3.7) 0.001
53.1 2.5 (2.0–3.2) 0.001
42.0 1.0 (0.8–1.2) 0.81
13.4 1.2 (0.9–1.6) 0.20
15.1 1.7 (1.3–2.2) 0.001
12.4 1.4 (1.1–1.9) 0.01
61.9 1.5 (1.2–1.9) 0.001
20.5 1.3 (1.0–1.7) 0.03
0.4 0.2 (0.0–1.2) 0.08
0.5 0.9 (0.2–3.6) 0.89
6.8 2.1 (1.5–2.9) 0.001
3.1 1.3 (0.7–2.3) 0.48
5.0 2.8 (1.9–3.9) 0.001
14.5 2.2 (1.7–2.8) 0.001
13.4 3.4 (2.6–4.3) 0.001
1.0 0.3 (0.1–0.7) 0.008
4.6 1.4 (0.9–2.2) 0.11
0.5 2.6 (1.1–6.1) 0.03
1.0 1.3 (0.4–4.1) 0.61
5.3 2.2 (1.5–3.2) 0.001
4.3 1.2 (0.7–2.0) 0.51
1.0 0.5 (0.2–1.3) 0.14
12.1 4.2 (3.4–5.3) 0.001
0.5 0.5 (0.1–3.3) 0.45
2.0 4.8 (3.4–6.6) 0.001
5.1 3.0 (2.2–3.9) 0.001
10.5 1.8 (1.4–2.3) 0.001
2.7 4.3 (3.2–5.8) 0.001
0.4 2.4 (1.0–5.5) 0.05
4.3 0.9 (0.5–1.6) 0.68Atriain, Coout Mbjec
rs on
ubjec
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July 19, 2011:395–401 The ATRIA Hemorrhage Risk Prediction Scoreidentified a comparatively large proportion of the cohort as
either low or high risk (Table 5). In contrast, other risk
schemes either led to much smaller fractions of the cohort
categorized as high risk or observed relatively low event rates
in their high-risk category. The ATRIA study scheme led to
sizable net reclassification improvement when compared
with all other risk schemes, ranging from 27.7% to 56.6%
improvement (Table 5).
Discussion
Accurate prediction of hemorrhage risk on warfarin is vital
to the anticoagulation therapy decision. Based on 5 easily
available clinical variables, the ATRIA score reflects the
experience of a large, diverse group of patients with atrial
fibrillation assembled from community care and followed up
for a longer period than prior studies. The model develop-
ment used rigorous contemporary methods such as split-
sample testing and bootstrap sampling approaches to un-
derwrite internal validity.
Final ATRIA Risk Score: Model Regression Coefficients and Hazardrom Derivation, Validation, and Combined hortsTable 3 Fi al ATRIA Risk Score: Model Regre sion CoefficientsFrom Derivation, Validation, and Combined Cohorts
Derivation Coho
Variable Points
Regression
Coefficient
Anemia 3 1.19
Severe renal disease* 3 0.97
Age 75 yrs 2 0.71
Any prior hemorrhage diagnosis 1 0.52
Diagnosed hypertension 1 0.27
*Defined as estimated glomerular filtration rate 30 ml/min or dialysis-dependent.
ATRIA  Anticoagulation and Risk Factors in Atrial Fibrillation.
Observed Major Bleeding Rates by Risk Score and Risk Category FTable 4 Observed Major Bleeding Rates by Risk Score and Ris
Derivation Cohort
Events/PY Events/100 PY
Risk score, points*
0 12/3,415 0.35
1 26/4,925 0.53
2 40/3,757 1.06
3 53/5,998 0.88
4 44/1,623 2.71
5 42/663 6.34
6 53/1,089 4.87
7 17/285 5.97
8 2/45 4.43
9 14/102 13.78
10 4/23 17.74
Risk category, points*
Low (0–3) 131/18,094 0.72
Intermediate (4) 44/1,623 2.71
High (5–10) 132/2,205 5.99
Overall 307/21,923 1.40 1*Three points for anemia, severe renal disease (estimated glomerular filtration rate 30 ml/min or on d
PY  person-years.When collapsed into a 3-category risk score, the ATRIA
study risk scheme was able to identify sizable proportions of
patients who fell into the most clinically meaningful cate-
gories, namely, low or high risk for hemorrhage. The
low-risk category, accounting for 83% of follow-up, had an
observed major hemorrhage rate of 1% per year. The
high-risk category represented only 10.2% of patient
follow-up yet accounted for 42% of the major bleeding
events. The ATRIA study scheme led to improvements in
accurate net reclassification when compared to alternative
schemes. The c-index of 0.74, while not representing
perfect discrimination, indicates good performance for a
prediction model and compares favorably to other widely
used risk stratification schemes such as the CHADS2
(congestive heart failure, hypertension, age 75 years,
diabetes mellitus, and stroke) stroke risk index, which has a
c-index of0.6 (15). Certainly, identifying novel predictors
of bleeding and improving current methods of risk stratifi-
cation are important areas of further investigation.
osHazard Ratios
Validation Cohort Combined Cohort
Regression
Coefficient
Hazard
Ratio
Regression
Coefficient
Hazard
Ratio
1.17 3.22 1.18 3.27
0.88 2.40 0.93 2.53
0.65 1.92 0.69 1.99
0.28 1.32 0.44 1.56
0.43 1.54 0.32 1.38
Each Cohortegory From Each Cohort
Validation Cohort Combined Cohort
/PY Events/100 PY Events/PY Events/100 PY
,879 0.48 21/5,294 0.40
,395 0.58 40/7,320 0.55
,806 0.78 54/5,563 0.97
,990 1.27 91/8,988 1.01
46 2.41 62/2,369 2.62
11 4.18 55/973 5.65
07 5.11 84/1,696 4.95
41 3.56 22/426 5.17
7 23.11 6/62 9.61
9 10.13 20/161 12.43
2 16.34 6/35 17.25
,071 0.83 206/27,166 0.76
46 2.41 62/2,369 2.62
,147 5.32 193/3,353 5.76
0,965 1.40 461/32,888 1.40Ratiand
rt
Hazard
Ratio
3.28
2.63
2.03
1.68
1.31romk Cat
Events
9/1
14/2
14/1
38/2
18/7
13/3
31/6
5/1
4/1
6/5
2/1
75/9
18/7
61/1
54/1ialysis); 2 points for age 75 years; 1 point for prior bleeding, hypertension.
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The ATRIA Hemorrhage Risk Prediction Score July 19, 2011:395–401The variables in our model have each been linked to
increased hemorrhage risk in prior studies (5-10). Anemia
was strongly associated with future bleeding risk. Although
we were unable to determine the mechanism of association,
anemia may reflect a predisposition to hemorrhage or recent
subclinical hemorrhage. Severe renal disease was also a
powerful predictor of hemorrhage risk. All-cause prior
bleeding was associated with future bleeding, and presum-
ably identifies patients with a potential bleeding lesion or
diathesis. Finally, older age and hypertension were indepen-
dently associated with hemorrhage risk. Similar to other
hemorrhage risk schemes, this analysis focused on all-cause
major hemorrhage, both intracranial and extracranial. Al-
though intracranial hemorrhages are the most important
outcomes, the rarity of such events makes their risk predic-
tion challenging (16). High-quality models to predict intra-
cranial hemorrhage are vitally needed.
Our risk model is clinically applicable when counseling
patients about the relative benefits and harms of anticoag-
ulation therapy. Particularly as newer, easier to administer
anticoagulants become available, accurate estimates of hem-
Figure 1 Distribution of Cohort Person-Years and Hemorrhage E
Blue bars show the proportion of cohort person-years in low, intermediate, and hig
proportion of the total hemorrhage events (n  461) captured by each risk catego
Comparison of Risk Stratification Capacity (% Cohort PY), Annualizc-Index, and Net Reclass Im rovement Across HemorrhageTable 5 Comparison of Risk Str tificatio apacity (% Cohort Pc-Index, and Net Reclassification Improvement Across
Risk Scheme (Ref. #)/
First Author (Ref. #)
Low Risk
Intermediate
Risk
% PY Rate % PY Rate
ATRIA risk score 82.6 0.76 7.2 2.62
Outpatient Bleeding Index (5) 10.1 0.39 83.0 1.31
Kuijer et al. (6) 7.2 0.42 77.7 1.40
Kearon et al. (7) 58.2 0.61 38.7 2.27
HEMORR2HAGES (8) 65.9 0.72 29.0 2.49
Shireman et al. (9) 78.6 0.87 20.3 3.18
RIETE risk scheme (10) 37.6 0.56 62.0 1.86
*The c-index calculated when risk schemes were separated into 3 categories (low, intermediate
improvement calculated using the method of Pencina et al. (14).
Abbreviations as in Table 1.orrhage risk will strongly influence the anticoagulation
decision. Our risk score may not affect the anticoagulation
therapy decision for most patients at high risk for stroke,
because they derive a large benefit from anticoagulation.
However, bleeding risk is significantly more influential in
patients at moderate or lower stroke risk. Our bleeding risk
estimates can be incorporated into formal decision-analysis
models or can be used to counsel individual patients about
their estimated risks of stroke and bleeding. For such
patients, providing estimates of the risk of bleeding on
anticoagulation can be a very informative addition to indi-
vidualized patient decision making.
There are several limitations to our analysis. Our assess-
ment of clinical risk factors was based on computerized
databases that did not have information on several covariates
such as measurements of blood pressure and genotype. We
lacked information about nonprescription use of aspirin or
nonsteroidal anti-inflammatory drugs. Although the hem-
orrhage rate in the ATRIA study was generally lower than
that described by the other risk schemes, the rates are
similar to some recent randomized trials (17). Finally, it
s by Risk Categories
ding risk categories. Purple bars show the
IA  Anticoagulation and Risk Factors in Atrial Fibrillation.
ajor Hemorrhage Rate,Schemesnnualiz d Major Hemorrhage Rate,
orrhage Risk Schemes
h Risk c-Index (95% CI)
for 3 Category
Scores*
c-Index (95% CI)
for Continuous
Scores†
Net
Reclassification
Improvement‡Rate
5.76 0.69 (0.66–0.71) 0.74 (0.72–0.76) Referent
3.96 0.59 (0.58–0.61) 0.68 (0.65–0.70) 50.5%
1.89 0.56 (0.55–0.58) 0.57 (0.54–0.59) 56.6%
5.53 0.67 (0.65–0.69) 0.69 (0.67–0.71) 27.7%
3.96 0.67 (0.65–0.70) 0.71 (0.69–0.73) 28.9%
6.72 0.64 (0.61–0.66) 0.70 (0.68–0.73) 33.4%
10.20 0.63 (0.61–0.66) 0.68 (0.65–0.70) 44.8%
†The c-index calculated when risk schemes were in a continuous format. ‡Net reclassificationvent
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July 19, 2011:395–401 The ATRIA Hemorrhage Risk Prediction Scorewill be important to test the ATRIA study risk scheme in
a separate population. Although internal validation re-
duces the likelihood of chance playing a major role in
development of our model, external validity needs to be
tested empirically.
The risk of anticoagulant-associated hemorrhage is a
major deterrent to more widespread use of anticoagulants.
Risk stratification schemes can help clinicians estimate the
magnitude of hemorrhage risk when prescribing or continu-
ing anticoagulant therapy. Such schemes can also provide
important information for comparing the hemorrhage risk
of patients enrolled in clinical studies or when comparing
the safety of different anticoagulation strategies (18).
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APPENDIX
For a list of ICD-9 codes for hemorrhage outcomes,
please see the online version of this article.
